Liposomal Bupivacaine in Paravertebral Block for the Treatment of Pain After Video-assisted Thoracoscopic Lobectomy
- Conditions
- Chronic PainAcute PainPostoperative Pain
- Interventions
- Registration Number
- NCT06569953
- Brief Summary
The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.
- Detailed Description
Researchers will compare liposomal bupivacaine to bupivacaine to see if liposomal bupivacaine works better to treat acute and chronic pain after video-assisted thoracoscopic lobectomy.Participants will:1.Received liposomal bupivacaine or bupivacaine paravertebral block before surgery. 2.Keep a diary of their pain scores within 30min after recovery from anesthesia and 6h, 12h, 24h, 48h, 72h and 90d after the beginning of injection of experimental drugs.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 284
- Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia.
- Participants were 18 years or older.
- 18 kg/m2≤BMI≤30 kg/m2
- Participants with American Society of Anesthesiology (ASA) physical status I-III.
- Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily.
- with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III/IV,Ischemic stroke.
- with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment.
- with sensory disorders such as hyperalgesia.
- with other bodily pain.
- allergy to amide-type local anesthetics or any of the trial drugs
- taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h.
- with a history of alcohol or opioid abuse.
- who were pregnant or lactating.
- who were currently included in another clinical study within 3 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intervention (liposomal bupivacaine） Liposomal bupivacaine Participants randomized to the intervention arm received liposomal bupivacaine for paravertebral block before surgery. control (bupivacaine hydrochloride) Bupivacaine Hydrochloride Participants randomized to the intervention arm received bupivacaine hydrochloride for paravertebral block before surgery.
- Primary Outcome Measures
Name Time Method The incidence of chronic postoperative pain postoperative day (POD) 90 The incidence of chronic postoperative pain at 90 days
Area under the movement-evoked pain intensity-time curve from 0-72 hours after the intervention Area under the pain intensity-time curve in the movement (or coughing) state within 72h after the intervention.
- Secondary Outcome Measures
Name Time Method Area under the rest pain intensity-time curve from 0-72 hours after the intervention Area under the pain intensity-time curve at rest within 72h after the intervention.
Movement-evoked pain score 30 minutes after recovery from anesthesia,6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)
Proportion of participants who did not use rescue analgesia from 0-72 hours after the intervention Proportion of participants who did not use rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after the intervention.
Score of satisfaction with analgesia At 72 hours after the intervention At 72 hours after the intervention,the participants rated the satisfaction with analgesia.Satisfaction rating scale 0-5,where 0 was poor drug effectiveness, and 5 was excellent drug efficacy)
The cumulative dosage of rescue analgesia from 0-72 hours after the intervention The cumulative dosage of rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72hours and 0-72hours after the intervention.
Length of hospital stay From date of surgery until the date of first hospital discharge，assessed up to 1 months Duration of participants from hospital admission to hospital discharge
Chronic pain score postoperative day (POD) 90 Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score at 90 days after surgery.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)
Pain score at rest 30 minutes after recovery from anesthesia,6 hours,12hours, 24hours , 48hours and 72 hours after the intervention Use pain Numeric Rating Scale(NRS) to evaluate the pain score at rest at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)
The time of first use of rescue analgesia from 0-72 hours after the intervention The time of first use of rescue analgesia
First time out-of-bed From date of surgery until the date of first out-of-bed，assessed up to 7 days Time of participant's first out-of-bed activity after surgery
Trial Locations
- Locations (1)
The Second Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China